Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-10-16
2007-10-16
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C424S009100, C424S184100, C436S501000
Reexamination Certificate
active
10001067
ABSTRACT:
This invention provides methods of diagnosing and treating any C. pneumoniae infection of the skin includingC. pneumoniae-associated diseases such as cutaneous T-cell lymphoma (CTCL), mycosis fungoides, Sézary syndrome, lymphomatoid papillosis, Ki-1 lymphoma, exfoliative exematous rash, and digitate parapsoriasis. This invention provides kits that are useful in the methods of the invention as well as for identifying new anti-chlamydial agents in treating skin infections. This invention includes a pharmaceutical vaccine composition comprising an antigen, including a full length antigenic determinant, such as any SAF positive determinant or portion thereof, which produces a detectable immune, humoral and/or cellular response toC. pneumoniae. The invention also includes a method of treating an active CTCL in a living being comprising delivering a therapeutically effective amount of a vaccine, wherein the vaccine comprises an agent, such as an inactivatedC. pneumoniaematerial that produces a detectable immune, humoral and/or cellular response.
REFERENCES:
patent: 5427781 (1995-06-01), DeFreitas et al.
RoBler et al., “No evidence of skin infection withChlamydia pneumoniaein patients with cutaneous T cell Lymphoma.” Clinical Microbiology and Infectious Diseases, CMI,vol. 9, No. 7, Jul. 2003, pp. 721-723.
Abrams et al., “Sezary T-Cell activating factor is aChlamydia pneumoniae-associated protein.” Clinical and Diagnostic Laboratory Immunology, Nov. 1999, vol. 6, No. 6, pp. 895-905.
Blasi et al., “Chlamydia pneumoniae.” Clinical Pulmonary medicine, 2002, 9/1, pp. 6-12. Abstract Only.
Langtry et al., “Azitromycin A review of its use in pediatric infectious diseases.” Drugs, 1998, 56(2) pp. 273-297.
Abrams et al., “Association between Sezary T Cell Activating Factor,Chlamydia pneumoniae, and cutaneous T cell lymphoma,” Annals of the New York Academy of Sciences, vol. 941, Sep. 2001, pp. 69-85.
Paulli and Berti, Haematologica, 2004, vol. 89, pp. 1372-1388.
Tan R. S. -H et al., Mycosis fungoides—a disease of antigen persistence, British J. Dermatol., 1974; 91:607-616.
Gazdar A.F. et al., In Vitro Growth of Cutaneous T-Cell Lymphomas, Cancer Treatment Reports, 1979; 63:587-590.
Haynes B.F. et al., Cell Surface Differentiation Antigens of the Malignant T Cell in Sézary Syndrome and Mycosis Fungoides, J. Clin. Investig., 1981; 67:523-530.
Edelson R.L., Pathogenesis of T cell lymphoma of skin, Amer. Acad. Dermatol., 1983; 9:957-960.
Golstein M.M. et al., An OKT4+T-Cell Population in Sézary Syndrome: Attempts to Elucidate Its Lack of Proliferative Capacity and Its Suppressive Effect, Scand. J. Immunol., 1986; 23:53-64.
Whittum-Hudson J.A. et al., Changes in conjunctival Lymphocyte populations induced by oral immunization withChlamydia trachomatis, Current Eye Research, 1986; 5:973-979.
Sterry W. et al., CD4+ Cutaneous T-Cell Lymphomas Show the Phenotype of Helper/Inducer T Cells (CD45RA-, CDw29+), J. Invest. Dermatol., 1989; 93:413-415.
Abrams J.T. et al., A Clonal CD4-Positive T-Cell Line Established from the Blood of a Patient with Sezary Syndrome, J. Invest. Dermatol., 1991; 96:31-37.
Abrams J.T. et al., Malignant and Nonmalignant T Cell Lines From Human T Cell Lymphotropic Virus Type I-Negative Patients With Sézary Syndrome, J. Immunol., 1991; 146:1455-1462.
Hunt S.J. et al., Cutaneous T-cell lymphoma: Utility of lymphoma: Utility of antibodies to the variable regions of the human T-cell antigen receptor, J. Amer. Acad. Dermatol., 1992; 26:552-558.
Vowels B.R. et al., Extracorporeal Photochemotherapy Induces the Production of Tumor Necrosis Factor-α by Monocytes: Implications for the Treatment of Cutaneous T-Cell Lymphoma and Systemic Sclerosis, J. Investig. Dermatol., 1992; 98:686-692.
Grayston J.T. et al.,Chlamydia pneumoniae, Strain Twar Pneumonia, Ann. Rev. Med., 1992; 43:317-23.
Leinonen M. et al., Pathogenetic mechanisms and epidemiology ofChlamydia pneumoniae, Eur. Heart J., 1993; 14 (Supplement K):57-61.
Gran J.T. et al., Pneumonia, Myocarditis and Reactive Arthritis due toChlamydia pneumoniae, Scand. J. Rheumatol., 1993; 2:43-44.
Beatty W.L. et al., Morphologic and antigenic characterization of interferon γ-mediated persistentChlamydia trachomatisinfection in vitro, Proc. Natl. Acad. Sci. USA, 1993; 90:3998-4002.
Abrams J.T. et al., Sézary T-Cell-activating Factor Induces Functional Interleukin 2 Receptors on T-Cells Derived from Patients with Sézary Syndrome, Cancer Res., 1993; 53:5501-5506.
Simon A.K. et al., Analysis of cytokine profiles in synovial T cell clones from chlamydial reactive arthritis patients: predominance of the Th1 subset, Clin. Exp. Immunol. 1993; 94:122-126.
Fivenson D.P. et al., Localization of clonal T cells to be epidermis in cutaneous T-cell lymphoma, J. Amer. Acad. Dermatol., 1994; 31:717-723.
Mielke V. et al., Clonal Disease In Early Cutaneous T-Cell Lymphoma, Dermatologic Clinics, 1994; 12:351-360.
Campbell L.C. et al., Detection ofChlamydia pneumoniaeTWAR in Human Coronary Atherectomy Tissues, J. Infect. Dis., 1995; 172:585-588.
Hyman C.L. et al. Prevalence of Asymptomatic Nasopharyngeal Carriage ofChlamydia pneumoniaein Subjectively Healthy Adults: Assessment by Polymerase Chain Reaction-Enzyme Immunoassay and Culture, Clin. Infect. Dis., 1995; 20:1174-8.
Sarris A.H. et al., Cytokine Loops Involving Interferon-γ and IP-10, a Cytokine Chemotactic for CD4+Lymphocytes: An Explanation for the Epidermotropism of Cutaneous T-Cell Lymphoma?, Blood, 1995; 86:651-658.
Koskiniemi M. et al.,Chlamydia pneumoniaeAssociated with Central Nervous System Infections, Europ. Neurol., 1996; 36:160-163.
Koehler L. et al., Ultrastructural and molecular analyses of the persistence ofChalymdia trachomatis(serovar K) in human monocytes, Microbial Pathogenesis 1997; 22:133-142.
Jackow C.M. et al., Association of Erythrodermic Cutaneous T-Cell Lymphoma, Superantigen-PositiveStaphylococcus aureus, and Oligoclonal T-Cell Receptor V B Gene Expansion, Blood, 1997; 89:32-40.
Balin B.J. et al., Identification and localization ofChlamydia pneumoniaein the Alzheimer's brain, Med. Microbiol. Immunol., 1998; 187:23-42.
J. Todd Abrams, Eric C. Vonderheid, Sonya Kolbe, Denah M. Appelt, E. James Arking, and Brian J. Balin. Sezary T-Cell Activating Factor is aChlamydia pneumoniae-Associated Protein. Clinical and Diagnostic Laboratory Immunology, Nov. 1999, p. 895-905, vol. 6, No. 6.
J. Todd Abrams, Subrata K. Ghosh, and Elaine DeFreitas. Sezary T-Cell activating Factor Induces Functional Interleukin 2 Receptors on T-Cells Derived from Patients with Sezary Syndrome. Cancer Research 53, 5501-5506, Nov. 15, 1993).
Antimicrobial effects of phototherapy and photochemotherpay in vivo and in vitro. M Yoshimura, S.Namura, H. Akamatsu and T. Horio, British Journal of Dermatology 1996; 135:528-532.
Diabetic Foot Ulcers andChlamydia pneumoniae: Innocent Bystander or Opportunistic Pathogen? (Reprinted) Arch Dermatol/vol. 137, May 2001.
Chlamydia pneumoniaeAssociated with Central Nervous System Infections Eur Neurol 1996:36:160-163.
Abrams J. Todd
Balin Brian J.
Caesar Rivise Bernstein Cohen & Pokotilow Ltd.
Intracell, LLC
Le Long V.
Look Lisa V.
LandOfFree
Compositions, methods and kits for diagnosis and treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions, methods and kits for diagnosis and treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions, methods and kits for diagnosis and treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3847653